In adults with moderate-to-severe osteoarthritis, subcutaneous tanezumab administration led to

remarkable improvements in work productivity, health status, and non-work activities at week 16.

This exploratory pooled analysis of two large phase III osteoarthritis studies aimed to determine tanezumab's effect on health status, work productivity, and non-work activities in osteoarthritis patients.

In people suffering from osteoarthritis of the knee or hip, subcutaneous tanezumab (5 mg, 2.5 mg) was investigated in placebo-controlled, double-blind, 16-week and 24-week clinical trials. At the baseline and 16th week, all the people finished the EQ-5D-5L (health-related, quality of life questionnaire) and the Work Productivity and Activity Impairment-osteoarthritis (WPAI-OA) activity impairment item.

People who were currently employed also finished the WPAI-OA work time missed, overall work impairment items, and impairment while working. With the aid of analysis of covariance, the between-group differences in the least squares mean alterations from baseline at week 16 were evaluated.

Out of 1545 pooled people, 576 people were employed at the baseline. Compared to placebo, the tanezumab 2.5-mg group exhibited substantial improvements in EQ-5D-5L index value, percent improvements in activity impairment, impairment while working, and overall work disability at the 16th week.

The results for the 5-mg tanezumab group were similar to the 2.5-mg tanezumab group. However, the percent improvement in the work time missed was considerably higher for the 5-mg tanezumab group, but not the 2.5-mg tanezumab group when compared to the placebo group.

Compared with placebo, the monoclonal antibody tanezumab substantially improved the health status, non-work activities, and work productivity in people having osteoarthritis of knee or hip.